Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 3049 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 22 23 24 ... 29 30 31  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Celyad–Horizon Discovery: shRNA technology, 201810– license excl to develop allogeneic CAR-T cell therapies 2018-10-04
GenAhead Bio–ERS Genomics: CRISPR technology, 201810– license non-excl to CRISPR/Cas9 genome editing IP of ERS Genomics Ltd 2018-10-04
Iqvia–United Kingdom (govt): clinical genomics, 201810– collab to develop integrated platform with clinical + genomics data with Genomics England 2018-10-04
Arcis:Altos–SEVERAL: investment, 201810 financing round £1.25m of Arcis Biotechnology from existing + new investors 2018-10-02
Arcis:Altos–SEVERAL: investment, 201810– crowd funding round targeting £0.5m of Arcis Biotechnology via Capital Cell 2018-10-02
Evonetix–Magic Micro: DNA synthesis technology, 201810– collab developm of MEMS for DNA synthesis with LioniX Intl 2018-10-01
Forbion–SEVERAL: investment, 201810 final close €360m of Forbion IV fund 2018-10-01
Owlstone–Foxconn: investment, 201810 financing round totalling additional $35m incl new + co-investor Foxconn Technology Group 2018-10-01
Owlstone–Horizons Ventures: investment, 201810 financing round totalling additional $35m incl existing + lead investor Horizons Ventures 2018-10-01
Owlstone–SEVERAL: investment, 201810 financing round additional $35m (£27m) bringing total to $50m led by Horizons Ventures 2018-10-01
Owlstone–Ventura Capital: investment, 201810 financing round totalling additional $35m incl new + co-investor Ventura Capital 2018-10-01
VelosBio–Arix Bioscience: investment, 201810 financing round Series A totalling $58m incl $11m from new + co-lead investor Arix Bioscience 2018-10-01
VelosBio–SEVERAL: investment, 201810 financing round Series A $58m co-led by new investors Arix Bioscience + Sofinnova Ventures 2018-10-01
VelosBio–Sofinnova: investment, 201810 financing round Series A totalling $58m incl new + co-lead investor Sofinnova Ventures 2018-10-01
Tusk Therapeutics–Roche: investment, 201809 acquisition for €70m cash + €585m milestones with some assets spun out into Black Belt Therapeutics 2018-09-28
TTP Group–Battery Ventures: investment, 201810 acquisition €na of TTP Labtech from TTP Group by Battery Ventures 2018-09-27
Nightstar Therapeutics–SEVERAL: investment, 201809 Public Offering $72m+$10.8m with 4m+600k ADS at $18/ADS 2018-09-25
Histologix–Intelligent Tissue Group: investment, 201809 acquisition of Histologix Ltd by The Intelligent Tissue Group Ltd 2018-09-20
Oxford Genetics–ERS Genomics: CRISPR technology, 201809– license non-excl for CRISPR modified cell lines extended to APAC region 2018-09-20
Oxford VR–SEVERAL: investment, 201809 financing round £3.2m incl OSI + Univ Oxford + Force Over Mass et al 2018-09-20
Thermo Fisher–ERS Genomics: CRISPR technology, 201809– license ww non-excl rights to products + tools + services for research from ERS Genomics 2018-09-18
GamaMabs Pharma–Andrew Lloyd Associates: public relations, 201809 service existent by ALA 2018-09-17
AstraZeneca–Horizon Discovery: genomic libraries, 201809– supply adoption of Edit-R crRNA libraries for funcitonal genomics discovery platform by AZ 2018-09-14
Applied Microarrays–Novacyt: DNA microarrays, 201809– €na collab developm probes for customised SNP microarrys by Primerdesign 2018-09-13
Cell Medica–United Kingdom (govt): cell therapy manfucturing, 201809 supply existent Cell Medica uses CGT Catapult manufacturing centre in Stevenage 2018-09-11
Freeline Therapeutics–United Kingdom (govt): gene therapy manfucturing, 201809 supply Freeline uses CGT Catapult manufacturing centre in Stevenage 2018-09-11
Optibrium–Intellegens: drug discovery software, 201809– collab providing Optibrium clients access to Intellegens’ Alchemite AI technology 2018-09-11
Arecor–Albion Ventures: investment, 201809 financing round totalling £6m incl co-lead investor Albion Capital 2018-09-10
Arecor–Calculus Capital: investment, 201809 financing round totalling £6m incl co-lead investor Calculus Capital 2018-09-10
Arecor–Downing: investment, 201809 financing round totalling £6m incl co-lead investor Downging Ventures 2018-09-10
Arecor–SEVERAL: investment, 201809 financing round £6m co-led by Calculus Capital + Downing Ventures + Albion Capital 2018-09-10
Merck (DE)–AstraZeneca: digital pathology, 201809– collab multi-year partnership with Definiens using TissuePhenomics for biomarker quantification 2018-09-10
Novate Medical–BTG: investment, 201809 acquisition $20m cash upfront + $130m milestones of Novate Medical Ltd by BTG plc 2018-09-07
Adaptimmune–Matrix Capital Manamagent: investment, 201809 registered direct offering totalling $100m incl existing investor Matrix Capital 2018-09-05
Adaptimmune–New Enterprise Associates: investment, 201809 registered direct offering totalling $100m incl existing investor NEA 16 LP + NEA 14 LP 2018-09-05
Adaptimmune–SEVERAL: investment, 201809 registered direct offering $100m of 10m ADSs at $10/ADS to Matrix Capital + NEA + Syncona 2018-09-05
Adaptimmune–Wellcome Trust: investment, 201809 registered direct offering totalling $100m incl new investor Syncona Portfolio Ltd 2018-09-05
Optibrium–Enamine: chemical compound libraries, 201809– collab free access to EnamineStore database for StarDrop users 2018-09-04
Evox Therapeutics–Alphabet: investment, 201809 financing round Series B totalling £35.5m incl new investor GV 2018-09-03
Evox Therapeutics–Borealis Ventures: investment, 201809 financing round Series B totalling £35.5m incl new investor Borealis Ventures 2018-09-03
Evox Therapeutics–Cowen: investment, 201809 financing round Series B totalling £35.5m incl new investor Cowen Healthcare Investments 2018-09-03
Evox Therapeutics–OTHER: investment, 201809 financing round Series B totalling £35.5m incl small number of private investors 2018-09-03
Evox Therapeutics–Panacea Venture: investment, 201809 financing round Series B totalling £35.5m incl new investor PHV 2018-09-03
Evox Therapeutics–Redmile Group: investment, 201809 financing round Series B totalling £35.5m incl new + lead investor Redmile Group 2018-09-03
Evox Therapeutics–SEVERAL: investment, 201809 financing round Series B £35.5m led by Redmile Group 2018-09-03
Evox Therapeutics–Univ Oxford: investment, 201809 financing round Series B totalling £35.5m incl existing investors OSI + Oxford Univ 2018-09-03
Genomics Medicine Ireland–Univ Cambridge: genomics, 201808– collab using 15000 DNA-extracted MS samples from biobank of Prof Sawcer 2018-08-30
Genomics plc–FTI Consulting: public relations, 201808 service existent by FTI Consulting 2018-08-30
Genomics plc–Invesco: investment, 201808 financing round Series B totalling £25m incl existing + co-investor Invesco Perpetual 2018-08-30
Genomics plc–IP Group: investment, 201808 financing round Series B totalling £25m incl existing + co-investor IP Group 2018-08-30
Genomics plc–Lansdowne Partners: investment, 201808 financing round Series B totalling £25m incl existing + co-investor Lansdowne Partners 2018-08-30
Genomics plc–SEVERAL: investment, 201808 financing round Series B £25m led by Vertex + incl IP Group + Woodford et al 2018-08-30
Genomics plc–Tanarra: investment, 201808 financing round Series B totalling £25m incl co-investor Tamorer Pty Ltd 2018-08-30
Genomics plc–Univ Oxford: investment, 201808 financing round Series B totalling £25m incl co-investor Oxford Sciences Innovation 2018-08-30
Genomics plc–Vertex: investment, 201808 financing round Series B totalling £25m incl lead investor Vertex in connection with collab 2018-08-30
Genomics plc–Woodford Investment: investment, 201808 financing round Series B totalling £25m incl existing + co-investor Woodford Investment 2018-08-30
Lunaphore–SEVERAL: investment, 201808 financing round Series B CHF5.3m from existing + new investors 2018-08-30
Vertex–Genomics plc: bioinformatics, 201808– collab expansion using human genetics + data science for target discovery + personalised medicine 2018-08-30
Kandy Therapeutics–Advent Life Sciences: investment, 201808 financing round Series C totalling £25m incl existing investor Advent Life Sciences 2018-08-29
Kandy Therapeutics–Forbion: investment, 201808 financing round Series C totalling £25m incl existing investor Forbion Capital Partners 2018-08-29
Kandy Therapeutics–Fountain Healthcare Partners: investment, 201808 financing round Series C totalling £25m incl existing investor Fountain HCP 2018-08-29
Kandy Therapeutics–Longitude Capital: investment, 201808 financing round Series C totalling £25m incl new investor Longitude Capital 2018-08-29
Kandy Therapeutics–OrbiMed: investment, 201808 financing round Series C totalling £25m incl existing investor OrbiMed 2018-08-29
Kandy Therapeutics–SEVERAL: investment, 201808 financing round Series C £25m from Longitude Capital + Advent LS + Fountain HCP + Forbion + OrbiMed 2018-08-29
Nebula Genomics–Heartbeat Labs: investment, 201808 seed financing round totalling $4.3m incl Heartbeat Labs 2018-08-29
Nebula Genomics–Hikma: investment, 201808 seed financing round totalling $4.3m incl Hikma Ventures 2018-08-29
Nebula Genomics–SEVERAL: investment, 201808 seed financing round $4.3m from ten leading tech + biotech VCs 2018-08-29
Congenica–Instinctif Partners: public relations, 201808 service existent by Instinctif 2018-08-28
Thermo Fisher–BioStrata: public relations, 201808 service existent by BioStrata 2018-08-27
SolasCure–Brain Biotech: investment, 201808–202108 financing round Series A totalling £15m incl lead investor Brain Biotech AG 2018-08-22
SolasCure–BRAIN Biotech: wound care product, 201808– license IP for Aurase enzyme + supply of enzymatic active ingredient by BRAIN to SolasCure 2018-08-22
SolasCure–SEVERAL: investment, 201808–202108 financing round Series A £15m led by Brain Biotech AG 2018-08-22
HackScience–SEVERAL: investment, 201808 seed financing round $1.8m 2018-08-20
Ziylo–Novo Group: investment, 201808 acquisition 100% for up to $800m in upfront + milestone payments by Novo Nordisk 2018-08-17
Abzena–Welsh Carson Anderson & Stowe: investment, 201808– recommended cash offer 16p/share valueing Abzena at £34.4m by WCAS XII-Astra LP 2018-08-16
Blueberry Therapeutics–Bryan Garnier: financial services, 201808 supply service financial advisor with regard to £10m Series B financing round 2018-08-14
Blueberry Therapeutics–China Medial System: investment, 201808 financing round Series B totalling £10m incl China Medical Venture Investment (HK) Ltd 2018-08-14
Blueberry Therapeutics–Onyx Health: public relations, 201808 service existent by Onyx Health PR 2018-08-14
Blueberry Therapeutics–PERSON: investment, 201808 financing round Series B totalling £10m incl investor A&B (HK) Ltd 2018-08-14
Blueberry Therapeutics–SEVERAL: investment, 201808 financing round Series B £10m from China Medical Venture Investment + A&B (HK) 2018-08-14
Blueberry Therapeutics–Slater Heelis: legal services, 201808 supply service legal advisor with regard to £10m Series B financing round 2018-08-14
Orchard Therapeutics–SEVERAL: investment, 201808 financing round Series C $150m led by Deerfield Management 2018-08-13
Artios Pharma–AbbVie: investment, 201808 financing round Series B totalling $84m incl existing + co-investor AbbVie Ventures 2018-08-10
Artios Pharma–Andera Partners: investment, 201808 financing round Series B totalling $84m (£65m) incl new + lead investors Andera Partners + LSP 2018-08-10
Artios Pharma–Arix Bioscience: investment, 201808 financing round Series B totalling $84m incl existing + co-investor Arix Bioscience 2018-08-10
Artios Pharma–IP Group: investment, 201808 financing round Series B totalling $84m incl existing + co-investor IP Group 2018-08-10
Artios Pharma–Life Sciences Partners: investment, 201808 financing round Series B totalling $84m incl new + lead investors Andera Partners + LSP 2018-08-10
Artios Pharma–Merck (DE): investment, 201808 financing round Series B totalling $84m incl existing + co-investor M Ventures 2018-08-10
Artios Pharma–Novartis: investment, 201808 financing round Series B totalling $84m incl new + co-investor Novartis Venture Fund 2018-08-10
Artios Pharma–Optimum Strategic Communications: public relations, 201808 service existent by Optimum 2018-08-10
Artios Pharma–Pfizer: investment, 201808 financing round Series B totalling $84m incl new + co-investor Pfizer Ventures 2018-08-10
Artios Pharma–SEVERAL: investment, 201808 financing round Series B $84m (£65m) led by new investors Andera Partners + LSP 2018-08-10
Artios Pharma–SV Health Investors: investment, 201808 financing round Series B totalling $84m incl existing + co-investor SV 2018-08-10
Quethera–Astellas: investment, 201808 acquisition for up to £85m in upfront + milestones payment 2018-08-10
Vernalis–Ligand: investment, 201808– recommended cash takeover offer £32.8m with £0.062/share ANNOUNCED 2018-08-09
Pharmaxis–Arix Bioscience: investment, 201808– primary placing totalling A$24m incl A$14.2m in two tranches from lead investor Arix Bioscience 2018-08-06
Pharmaxis–SEVERAL: investment, 201808– primary placing A$24m in two tranches led by Arix Bioscience 2018-08-06
United Kingdom (govt)–Bruker: NMR technology, 201808 supply £20m NMR technology to 8 UK universities funded by EPSRC + BBSRC + MRC +NERC 2018-08-06
Univ Birmingham–Bruker: NMR spectrometer, 201808 supply 1GHz NMR spectrometer 2018-08-06
Univ Warwick–Bruker: NMR spectrometer, 201808 supply Avance 1.0 GHz solid-state NMR spectrometer 2018-08-06
next pagenext page 1 2 3 ... 22 23 24 ... 29 30 31  next pagenext page



Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px

» top